应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06978 永泰生物-B
午间休市 05-20 09:00:01
3.200
+0.000
0.00%
最高
3.200
最低
3.200
成交量
0.00
今开
3.200
昨收
3.200
日振幅
0.00%
总市值
16.47亿
流通市值
16.47亿
总股本
5.15亿
成交额
0.00
换手率
0.00%
流通股本
5.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
中信建投:创新药产业持续升级,竞逐全球市场
36氪 · 07:10
中信建投:创新药产业持续升级,竞逐全球市场
翰宇药业董事、副总裁杨笛:中外创新药产业存在内因、外因两方面差异
华夏时报 · 05-19 21:03
翰宇药业董事、副总裁杨笛:中外创新药产业存在内因、外因两方面差异
中信建投:中国创新药授权出海进入收获期 长期关注这些主线
智通财经网 · 05-19 19:31
中信建投:中国创新药授权出海进入收获期 长期关注这些主线
登陆科创板16个月股价涨近7倍,百利天恒筹划赴港IPO,或刷新近年创新药企上市募资纪录
独角兽早知道 · 05-19 09:11
登陆科创板16个月股价涨近7倍,百利天恒筹划赴港IPO,或刷新近年创新药企上市募资纪录
企业出管线,资本出钱,恒瑞医药GLP-1类创新药组队出海
蓝鲸财经 · 05-17 20:48
企业出管线,资本出钱,恒瑞医药GLP-1类创新药组队出海
2023年国内PARP抑制剂销售额攀升:创新药“四雄”格局将迎变,仿制药竞争加剧
财经网 · 05-17
2023年国内PARP抑制剂销售额攀升:创新药“四雄”格局将迎变,仿制药竞争加剧
攻入美国市场,中国医药创新的iPhone时刻
市值观察 · 05-17
攻入美国市场,中国医药创新的iPhone时刻
医药行业第二次年度盛会临近,关注创新药研发进展
金融界 · 05-16
医药行业第二次年度盛会临近,关注创新药研发进展
海思科(002653.SZ)获得创新药HSK39004吸入混悬液IND申请受理
智通财经 · 05-15
海思科(002653.SZ)获得创新药HSK39004吸入混悬液IND申请受理
海思科最新公告:获得创新药HSK39004吸入混悬液IND申请受理通知书
证券之星 · 05-15
海思科最新公告:获得创新药HSK39004吸入混悬液IND申请受理通知书
创新药“出海”巨额交易遭质疑,百利天恒吃监管函
钛媒体APP · 05-15
创新药“出海”巨额交易遭质疑,百利天恒吃监管函
2023年研发投入最多的20款中国创新药,透露了什么风向?
格隆汇 · 05-15
2023年研发投入最多的20款中国创新药,透露了什么风向?
突破创新药出海记录后,百利天恒要闯港股
华尔街见闻 · 05-15
突破创新药出海记录后,百利天恒要闯港股
云顶新耀肾病创新药开出内地首张处方,称将参加今年国谈
澎湃新闻 · 05-14
云顶新耀肾病创新药开出内地首张处方,称将参加今年国谈
创客十问 | 维琪丁文锋:以创新向世界讲好中国成分故事
财经网 · 05-14
创客十问 | 维琪丁文锋:以创新向世界讲好中国成分故事
5月14日海特生物涨停分析:肝炎概念,中药,创新药概念热股
证券之星 · 05-14
5月14日海特生物涨停分析:肝炎概念,中药,创新药概念热股
百利天恒拟港股IPO,或刷新近年创新药企上市募资纪录
氨基观察 · 05-14
百利天恒拟港股IPO,或刷新近年创新药企上市募资纪录
【AH互动】药明康德(02359)续升逾6% 机构指政策红利下创新药及其产业链发展有望提速
金吾财讯 · 05-14
【AH互动】药明康德(02359)续升逾6% 机构指政策红利下创新药及其产业链发展有望提速
东阳光药研发能力居国内前列,未来陆续推出多款创新药上市
时代周报 · 05-14
东阳光药研发能力居国内前列,未来陆续推出多款创新药上市
加载更多
公司概况
公司名称:
永泰生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。
发行价格:
--
{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.2,"timestamp":1716166801291,"preClose":3.2,"halted":0,"volume":0,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.70124924,"marketStatus":"午间休市","marketStatusCode":3,"change":0,"latestTime":"05-20 09:00:01","open":3.2,"high":3.2,"low":3.2,"amount":0,"amplitude":0,"askPrice":3.24,"askSize":3000,"bidPrice":3.13,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.7012492319152587,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716181200000},"adr":0,"listingDate":1594310400000,"adjPreClose":3.2,"openAndCloseTimeList":[[1716168600000,1716177600000],[1716181200000,1716192000000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2436118591","title":"中信建投:创新药产业持续升级,竞逐全球市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2436118591","media":"36氪","top":-1,"share":"https://www.laohu8.com/m/news/2436118591?lang=zh_cn&edition=full","pubTime":"2024-05-20 07:10","pubTimestamp":1716160240,"startTime":"0","endTime":"0","summary":"36氪获悉,中信建投研报指出,近年来,随着中国创新药蓬勃发展,越来越多的中国药企将目标转向海外,以赢得更多的发展机会和市场份额,全球市场的大机会给予创新药出海动力。随着创新技术的不断迭代,中国创新药全球竞争力持续提升。在“三步走”的出海模式下,不断有中国创新药企成功出海走向世界。整体看,中国创新药授权...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240520A00LLY00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240520A00LLY00","is_publish_highlight":false,"gpt_icon":0},{"id":"2436164445","title":"翰宇药业董事、副总裁杨笛:中外创新药产业存在内因、外因两方面差异","url":"https://stock-news.laohu8.com/highlight/detail?id=2436164445","media":"华夏时报","top":-1,"share":"https://www.laohu8.com/m/news/2436164445?lang=zh_cn&edition=full","pubTime":"2024-05-19 21:03","pubTimestamp":1716123788,"startTime":"0","endTime":"0","summary":"本报(chinatimes.net.cn)记者颜源 于娜 上海报道5月16日下午,首届华夏大健康产业ESG发展大会暨2024“蒲公英指数”报告发布会在上海国家会展中心举办。本次大会为第88届药交会分论坛之一,以“追寻新质生产力·聚焦可持续发展”为主题,由华夏时报社华夏大健康研究院和国药励展共同主办。在“如何用全链条支持创新药发展...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/Ob7_I-3Fgl0o17nSMdKWyOJrGzjbhs0UVdrknIKJK7UwIAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Ob7_I-3Fgl0o17nSMdKWyOJrGzjbhs0UVdrknIKJK7UwIAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240519A07CDX00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240519A07CDX00","is_publish_highlight":false,"gpt_icon":0},{"id":"2436655169","title":"中信建投:中国创新药授权出海进入收获期 长期关注这些主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2436655169","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2436655169?lang=zh_cn&edition=full","pubTime":"2024-05-19 19:31","pubTimestamp":1716118301,"startTime":"0","endTime":"0","summary":"随着创新技术的不断迭代,中国创新药全球竞争力持续提升。在“三步走”的出海模式下,不断有中国创新药企成功出海走向世界。整体看,中国创新药授权出海进入收获期,2020年后国内药企license-out首付款及总额明显增长,未来可期。Q2开始,部分高基数因素逐步弱化,企业逐步适应合规新常态下的经营,中信建投预计整体增速将逐步企稳。拉长来看,目前全行业基金医药持仓比例已降至历史低位,中信建投认为行业面临的挑战已经充分预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122996.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2436137443","title":"登陆科创板16个月股价涨近7倍,百利天恒筹划赴港IPO,或刷新近年创新药企上市募资纪录","url":"https://stock-news.laohu8.com/highlight/detail?id=2436137443","media":"独角兽早知道","top":-1,"share":"https://www.laohu8.com/m/news/2436137443?lang=zh_cn&edition=full","pubTime":"2024-05-19 09:11","pubTimestamp":1716081060,"startTime":"0","endTime":"0","summary":"若港股上市成功,百利天恒将成为科创板第15家同时实现A股、港股同时两地上市的企业。此外,公司积极筹备赴港IPO,也是对国家相关政策的积极响应。最新消息显示,2024年3月份,百利天恒已收到由BMS支付的8亿美元首付款。百利天恒在财报中指出,研发费用高企主要系报告期内新药研发项目持续推进,试验检测费、知识产权使用费增幅较大,以及研发人员增加导致薪酬增长所致。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/hkzmt/2024-05-19/doc-inavtmnv7695422.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkzmt/2024-05-19/doc-inavtmnv7695422.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2436428916","title":"企业出管线,资本出钱,恒瑞医药GLP-1类创新药组队出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2436428916","media":"蓝鲸财经","top":-1,"share":"https://www.laohu8.com/m/news/2436428916?lang=zh_cn&edition=full","pubTime":"2024-05-17 20:48","pubTimestamp":1715950120,"startTime":"0","endTime":"0","summary":"5月16日,恒瑞医药宣布,将公司具有自主知识产权的GLP-1类创新药HRS-7535、HRS9531、HRS-4729在除大中华区以外的全球范围内开发、生产和商业化的独家权利有偿许可给美国Hercules公司。作为对外许可交易对价一部分,恒瑞医药将取得美国Hercules公司19.9%的股权。有业内人士指出,该种对外授权开创了一种新模式,类似于恒瑞医药联合几家投资机构,企业出管线,资本出钱,共同承载恒瑞医药的三款GLP-1类的管线出海业务。全球范围内尚无口服小分子GLP-1R激动剂上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/232189","is_publish_highlight":false,"gpt_icon":0},{"id":"2436761956","title":"2023年国内PARP抑制剂销售额攀升:创新药“四雄”格局将迎变,仿制药竞争加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2436761956","media":"财经网","top":-1,"share":"https://www.laohu8.com/m/news/2436761956?lang=zh_cn&edition=full","pubTime":"2024-05-17 10:40","pubTimestamp":1715913617,"startTime":"0","endTime":"0","summary":"当前,各大药企的2023年度财报已披露完毕,多款PARP抑制剂的年度销售金额也随之公开。根据财报数据,除氟唑帕利销售收入未见披露,其他三款国内获批的PARP抑制剂全年销售额均稳中有进。此外,辉瑞、君实生物的PARP抑制剂上市申请均获受理,两款新药已准备进场,国内PARP抑制剂市场的“四雄”竞争格局或将生变。值得注意的是...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240517A02MVG00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240517A02MVG00","is_publish_highlight":false,"gpt_icon":0},{"id":"2436955312","title":"攻入美国市场,中国医药创新的iPhone时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2436955312","media":"市值观察","top":-1,"share":"https://www.laohu8.com/m/news/2436955312?lang=zh_cn&edition=full","pubTime":"2024-05-17 10:22","pubTimestamp":1715912520,"startTime":"0","endTime":"0","summary":"作为全球“同类最佳”BTK抑制剂,泽布替尼目前已在全球70个市场获批多项适应症,目前泽布替尼在海内外放量提速,重磅炸弹药物潜力显现。过去的一年里,中国创新药“出海”捷报频传,许多药企成功闯关欧美市场,对外授权合作规模也再创新高。在国内,替雷利珠单抗已有11项适应症纳入国家医保目录,是目前纳入医保目录获批适应症数量最多的PD-1。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051710280787729e89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051710280787729e89&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435188726","title":"医药行业第二次年度盛会临近,关注创新药研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2435188726","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435188726?lang=zh_cn&edition=full","pubTime":"2024-05-16 08:56","pubTimestamp":1715820985,"startTime":"0","endTime":"0","summary":"ASCO年会将于5月31日至6月4日在芝加哥召开,此前于4月上旬召开的AACR也吸引了诸多国内知名药企、院校参与,公布的众多重磅临床数据带动医药行业关注度回升。国信证券提到,ASCO会议是每年临床数据展示的重要国际会议之一,近几年国内药企在该会议上的数据读出逐年增加,体现出国内药企的药物研发能力日渐增强。浙商证券提到,今年ASCO中国本土创新药企业多项数据入选口头摘要,快速口头摘要,临床科学研讨会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516085742876e36e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516085742876e36e1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435603635","title":"海思科(002653.SZ)获得创新药HSK39004吸入混悬液IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2435603635","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435603635?lang=zh_cn&edition=full","pubTime":"2024-05-15 19:08","pubTimestamp":1715771324,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)发布公告,公司子公司西藏海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通知书》,涉及药品:“HSK39004”。公告显示,HSK39004是公司自主研发的全新的具有独立知识产权的靶向小分子抑制剂,临床拟用于气道阻力为特征的阻塞性肺病(如COPD、哮喘)的治疗。根据国家药品监督管理局关于发布《化学药品注册分类及申报资料要求》的通告(2020年第44号)中化学药品注册分类的规定,本品属于化学药品1类。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121617.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435563874","title":"海思科最新公告:获得创新药HSK39004吸入混悬液IND申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2435563874","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435563874?lang=zh_cn&edition=full","pubTime":"2024-05-15 18:40","pubTimestamp":1715769628,"startTime":"0","endTime":"0","summary":"海思科公告,获得创新药HSK39004吸入混悬液IND申请受理通知书。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500031597.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435512216","title":"创新药“出海”巨额交易遭质疑,百利天恒吃监管函","url":"https://stock-news.laohu8.com/highlight/detail?id=2435512216","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2435512216?lang=zh_cn&edition=full","pubTime":"2024-05-15 17:43","pubTimestamp":1715766193,"startTime":"0","endTime":"0","summary":"图片由AI生成5月15日,百利天恒-U(688506.SH)发布公告,称公司收到监管工作函,涉及对象包括上市公司、董事、监事、高级管理人员、中介机构及相关人员。但对于监管函具体内容及相关事由等,百利天恒未具体公开。对此,钛媒体APP联系公司相关人士获悉,百利天恒收监管函的原因在于公司与百时美施贵宝(简称BMS,BMY.US)相...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OmZpigIxrOf0imHtj0pGuQNMbrosQrgbpQrgSGs-SdUgEAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OmZpigIxrOf0imHtj0pGuQNMbrosQrgbpQrgSGs-SdUgEAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240515A07QDK00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240515A07QDK00","is_publish_highlight":false,"gpt_icon":0},{"id":"2435577287","title":"2023年研发投入最多的20款中国创新药,透露了什么风向?","url":"https://stock-news.laohu8.com/highlight/detail?id=2435577287","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2435577287?lang=zh_cn&edition=full","pubTime":"2024-05-15 11:00","pubTimestamp":1715742051,"startTime":"0","endTime":"0","summary":"已上市产品仍是企业研发的重头戏","market":"sg","thumbnail":"https://img3.gelonghui.com/0dfb0-f156b0a0-4d09-4368-bbab-b82fe00176dd.jpg?guru_height=852&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/0dfb0-f156b0a0-4d09-4368-bbab-b82fe00176dd.jpg?guru_height=852&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/735352","is_publish_highlight":false,"gpt_icon":0},{"id":"2435572704","title":"突破创新药出海记录后,百利天恒要闯港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435572704","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2435572704?lang=zh_cn&edition=full","pubTime":"2024-05-15 10:39","pubTimestamp":1715740782,"startTime":"0","endTime":"0","summary":"“A+H”两地上市","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/905b7c39-e68b-402f-8518-00b2fd295236.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/905b7c39-e68b-402f-8518-00b2fd295236.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3714929","is_publish_highlight":false,"gpt_icon":0},{"id":"2435960765","title":"云顶新耀肾病创新药开出内地首张处方,称将参加今年国谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2435960765","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2435960765?lang=zh_cn&edition=full","pubTime":"2024-05-14 18:52","pubTimestamp":1715683920,"startTime":"0","endTime":"0","summary":"5月14日,云顶新耀的肾病创新药耐赋康在中国内地开出首张处方。2019年6月,云顶新耀与Calliditas签订独家授权许可协议,获得在大中华地区和新加坡开发以及商业化耐赋康的权利。该协议于2022年3月扩展,将韩国纳入云顶新耀的授权许可范围。长期以来,IgA肾病缺乏特异性治疗方案,加上患者发病年龄较轻,预后不佳,患者易进展至终末期肾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051418533587686712&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051418533587686712&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435479518","title":"创客十问 | 维琪丁文锋:以创新向世界讲好中国成分故事","url":"https://stock-news.laohu8.com/highlight/detail?id=2435479518","media":"财经网","top":-1,"share":"https://www.laohu8.com/m/news/2435479518?lang=zh_cn&edition=full","pubTime":"2024-05-14 17:05","pubTimestamp":1715677515,"startTime":"0","endTime":"0","summary":"“中国化妆品当下的现状是,在原料开发上投入太少,几乎没有太多人专注原创原料的开发。大部分都是从买国外原料、再从配方起步的工厂。”近期的一场公开交流里,有十亿级国货彩妆创始人直言,“即便有些口碑不错的国货产品,研发根基还是在国外。可若真正做研发,应该先从解决需要什么样的原料问题起步,再谈定制化的原创配...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240514A073IG00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240514A073IG00","is_publish_highlight":false,"gpt_icon":0},{"id":"2435630105","title":"5月14日海特生物涨停分析:肝炎概念,中药,创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435630105","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435630105?lang=zh_cn&edition=full","pubTime":"2024-05-14 15:31","pubTimestamp":1715671899,"startTime":"0","endTime":"0","summary":"证券之星消息,海特生物涨停收盘,收盘价29.77元。该股于10点43分涨停,未打开涨停,截止收盘封单资金为3804.01万元,占其流通市值1.05%。5月14日的资金流向数据方面,主力资金净流入4688.78万元,占总成交额28.39%,游资资金净流出2278.65万元,占总成交额13.8%,散户资金净流出2410.13万元,占总成交额14.59%。近5日资金流向一览见下表:该股为肝炎概念,中药,创新药概念热股,当日肝炎概念概念上涨2.19%,中药概念上涨1.24%,创新药概念上涨0.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051400016314.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435526404","title":"百利天恒拟港股IPO,或刷新近年创新药企上市募资纪录","url":"https://stock-news.laohu8.com/highlight/detail?id=2435526404","media":"氨基观察","top":-1,"share":"https://www.laohu8.com/m/news/2435526404?lang=zh_cn&edition=full","pubTime":"2024-05-14 11:27","pubTimestamp":1715657236,"startTime":"0","endTime":"0","summary":"2023年,是百利天恒进击的一年。先是顺利完成科创板IPO,募资,成为2023年在科创板上市仅有几家的生物医药企业之一;年底,又与百时美施贵宝就其在研双抗ADC药物BL-B01D1,达成高达83亿美元的重磅合作,创下ADC全球第一大BD纪录。进入2024,进击继续。3月11日,百利天恒公告已经收到百时美施贵宝8亿美元的合作首付款,管线...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OxJmau6nJv4wBtP3eoHi8_Cr8ta1R6rnFmID4KS-yZH6MAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OxJmau6nJv4wBtP3eoHi8_Cr8ta1R6rnFmID4KS-yZH6MAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240514A039QH00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240514A039QH00","is_publish_highlight":false,"gpt_icon":0},{"id":"2435532422","title":"【AH互动】药明康德(02359)续升逾6% 机构指政策红利下创新药及其产业链发展有望提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2435532422","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2435532422?lang=zh_cn&edition=full","pubTime":"2024-05-14 11:07","pubTimestamp":1715656035,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明康德 周中第二日续涨,截至发稿,涨6.28%,报42.3港元,成交额5.04亿港元。另外,A股药明康德涨势略逊,暂升2.58%,报47.38元人民币。药明康德在美国医疗保健领域的参与程度之深,已远超国会的讨论。其他消息方面,浙商证券认为,北京及广州出台全链条支持文件体现出政策对创新药的支持开始加码,期待后续有更多省市推出创新药支持政策,在政策红利下,我国创新药及其产业链的高质量发展有望提速。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MDI1YTMwZTQxYzhhNDE2OTgwYTUxYmYyODYyMzUwODkzNDM3NDk5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MDI1YTMwZTQxYzhhNDE2OTgwYTUxYmYyODYyMzUwODkzNDM3NDk5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936830","is_publish_highlight":false,"gpt_icon":0},{"id":"2435533859","title":"东阳光药研发能力居国内前列,未来陆续推出多款创新药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2435533859","media":"时代周报","top":-1,"share":"https://www.laohu8.com/m/news/2435533859?lang=zh_cn&edition=full","pubTime":"2024-05-14 09:01","pubTimestamp":1715648493,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司(以下简称“东阳光药”)成立于2003年,是港股上市公司东阳光长江药业(01558.HK)的母公司。今年3月,东阳光长江药业发布公告表示,母公司东阳光药正考虑以换股方式吸收合并东阳光长江药业,引起资本市场高度关注。5月10日,东阳光长江药业发布公告进一步表示,东阳光药已与东阳光长江药业订立合并协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202405143075611922.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.056},{"period":"1month","weight":-0.0883},{"period":"3month","weight":-0.2271},{"period":"6month","weight":-0.1185},{"period":"1year","weight":-0.1421},{"period":"ytd","weight":-0.36}],"compareEarnings":[{"period":"1week","weight":0.0311},{"period":"1month","weight":0.2032},{"period":"3month","weight":0.1967},{"period":"6month","weight":0.1203},{"period":"1year","weight":-0.0088},{"period":"ytd","weight":0.147}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.129933},{"month":2,"riseRate":0.5,"avgChangeRate":0.104699},{"month":3,"riseRate":0.25,"avgChangeRate":-0.117615},{"month":4,"riseRate":0.25,"avgChangeRate":-0.077145},{"month":5,"riseRate":0.5,"avgChangeRate":0.024627},{"month":6,"riseRate":1,"avgChangeRate":0.076348},{"month":7,"riseRate":0,"avgChangeRate":-0.09491},{"month":8,"riseRate":0.5,"avgChangeRate":-0.036515},{"month":9,"riseRate":0.25,"avgChangeRate":-0.028227},{"month":10,"riseRate":0.75,"avgChangeRate":0.082892},{"month":11,"riseRate":0.5,"avgChangeRate":-0.017056},{"month":12,"riseRate":0.75,"avgChangeRate":0.09355}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}